Published in Blood on November 01, 2005
A genomic approach to human autoimmune diseases. Annu Rev Immunol (2010) 2.10
Assessing the human immune system through blood transcriptomics. BMC Biol (2010) 1.86
Financial costs and personal consequences of research misconduct resulting in retracted publications. Elife (2014) 1.59
Platelets: versatile effector cells in hemostasis, inflammation, and the immune continuum. Semin Immunopathol (2011) 1.26
Peripheral blood gene expression profiling for cardiovascular disease assessment. Genomic Med (2008) 1.18
Cardiovascular risk in systemic autoimmune diseases: epigenetic mechanisms of immune regulatory functions. Clin Dev Immunol (2011) 0.92
Transcriptome profiling of whole blood cells identifies PLEK2 and C1QB in human melanoma. PLoS One (2011) 0.84
Genetic analysis of intracranial tumors in a murine model of glioma demonstrate a shift in gene expression in response to host immunity. J Neuroimmunol (2006) 0.83
Thrombotic antiphospholipid syndrome shows strong haplotypic association with SH2B3-ATXN2 locus. PLoS One (2013) 0.78
Findings of research misconduct. NIH Guide Grants Contracts (2015) 0.75
Genetic dissection of platelet function in health and disease using systems biology. Hematol Oncol Clin North Am (2013) 0.75
Findings of Research Misconduct. Fed Regist (2015) 0.75
LDLR and PCSK9 Are Associated with the Presence of Antiphospholipid Antibodies and the Development of Thrombosis in aPLA Carriers. PLoS One (2016) 0.75
Predicting the clinical status of human breast cancer by using gene expression profiles. Proc Natl Acad Sci U S A (2001) 13.30
International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum (1999) 7.67
Gene expression predictors of breast cancer outcomes. Lancet (2003) 6.99
Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus. Lancet (1983) 6.71
Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet (1990) 6.54
Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci U S A (1990) 4.59
Antiphospholipid antibodies and thrombosis. Lancet (1999) 4.40
Integrated modeling of clinical and gene expression information for personalized prediction of disease outcomes. Proc Natl Acad Sci U S A (2004) 2.74
Autoantibodies to phospholipid-binding plasma proteins: a new view of lupus anticoagulants and other "antiphospholipid" autoantibodies. Blood (1994) 2.66
Lupus anticoagulant is the strongest risk factor for both venous and arterial thrombosis in patients with systemic lupus erythematosus. Comparison between different assays for the detection of antiphospholipid antibodies. Thromb Haemost (1996) 1.88
The epidemiology of venous thromboembolism in the community. Thromb Haemost (2001) 1.86
Incidence of idiopathic deep venous thrombosis and secondary thromboembolism among ethnic groups in California. Ann Intern Med (1998) 1.86
Antiphospholipid antibodies and the antiphospholipid syndrome in systemic lupus erythematosus. A prospective analysis of 500 consecutive patients. Medicine (Baltimore) (1989) 1.71
Anti-annexin V antibody in systemic lupus erythematosus patients with lupus anticoagulant and/or anticardiolipin antibody. Am J Hematol (1994) 1.55
Lupus anticoagulant IgG's (LA) are not directed to phospholipids only, but to a complex of lipid-bound human prothrombin. Thromb Haemost (1991) 1.55
Validation of the Sapporo criteria for antiphospholipid syndrome. Arthritis Rheum (2000) 1.49
Heterogeneity of anticardiolipin antibodies defined by the anticardiolipin cofactor. J Immunol (1992) 1.47
Gene expression signatures for autoimmune disease in peripheral blood mononuclear cells. Arthritis Res Ther (2004) 1.14
Lupus anticoagulant activity is frequently dependent on the presence of beta 2-glycoprotein I. Thromb Haemost (1992) 0.92
Millennium Award. Proteomics for the development of DNA tolerizing vaccines to treat autoimmune disease. Clin Immunol (2002) 0.89
Antiprothrombin antibodies: detection and clinical significance in the antiphospholipid syndrome. Blood (1999) 0.89
The antiphospholipid syndrome. Annu Rev Med (2001) 0.86
Arachidonic acid metabolism in the human mast cell line HMC-1: 5-lipoxygenase gene expression and biosynthesis of thromboxane. Biochim Biophys Acta (1995) 0.83
From antiphospholipid syndrome to antibody-mediated thrombosis. Lancet (1997) 0.83
Genetics of antiphospholipid syndrome. Curr Rheumatol Rep (2004) 0.82
Lupus anticoagulants form immune complexes with prothrombin and phospholipid that can augment thrombin production in flow. Blood (1999) 0.79
Prothrombin and beta 2-glycoprotein I frequently contribute to antiphospholipid antibody interactions with phospholipids and the generation of abnormal waveform profiles in coagulation assays. Thromb Haemost (2003) 0.78
Antiphospholipid antibodies. A marker for thrombosis and recurrent abortion. Clin Rev Allergy (1994) 0.78
Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature (2005) 19.56
Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation. N Engl J Med (2015) 10.86
Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science (2005) 9.04
Retracted Genomic signatures to guide the use of chemotherapeutics. Nat Med (2006) 7.45
A pharmacogenetic versus a clinical algorithm for warfarin dosing. N Engl J Med (2013) 7.09
Gene expression predictors of breast cancer outcomes. Lancet (2003) 6.99
Retracted A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. N Engl J Med (2006) 6.69
A signalling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells. Nat Cell Biol (2004) 6.61
Standardizing global gene expression analysis between laboratories and across platforms. Nat Methods (2005) 6.23
Retracted An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer. J Clin Oncol (2007) 5.77
Dose of prophylactic platelet transfusions and prevention of hemorrhage. N Engl J Med (2010) 5.23
Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. J Clin Oncol (2008) 4.45
High-Dimensional Sparse Factor Modeling: Applications in Gene Expression Genomics. J Am Stat Assoc (2008) 3.92
Gene expression phenotypic models that predict the activity of oncogenic pathways. Nat Genet (2003) 3.78
Retracted Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial. Lancet Oncol (2007) 3.67
Evolution of adverse changes in stored RBCs. Proc Natl Acad Sci U S A (2007) 3.58
Effect of escitalopram on mental stress-induced myocardial ischemia: results of the REMIT trial. JAMA (2013) 3.48
A pathway-based classification of human breast cancer. Proc Natl Acad Sci U S A (2010) 3.30
Retracted Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer. JAMA (2008) 3.26
GATHER: a systems approach to interpreting genomic signatures. Bioinformatics (2006) 3.22
Clinical practice. Heparin-induced thrombocytopenia. N Engl J Med (2006) 3.11
An E2F1-dependent gene expression program that determines the balance between proliferation and cell death. Cancer Cell (2008) 3.07
Comparative effectiveness of warfarin and new oral anticoagulants for the management of atrial fibrillation and venous thromboembolism: a systematic review. Ann Intern Med (2012) 3.04
Effects of red-cell storage duration on patients undergoing cardiac surgery. N Engl J Med (2015) 3.03
A bistable Rb-E2F switch underlies the restriction point. Nat Cell Biol (2008) 2.91
E2Fs link the control of G1/S and G2/M transcription. EMBO J (2004) 2.81
Retracted Pharmacogenomic strategies provide a rational approach to the treatment of cisplatin-resistant patients with advanced cancer. J Clin Oncol (2007) 2.80
Integrated modeling of clinical and gene expression information for personalized prediction of disease outcomes. Proc Natl Acad Sci U S A (2004) 2.74
RNA aptamers as reversible antagonists of coagulation factor IXa. Nature (2002) 2.73
Gene expression profiling and genetic markers in glioblastoma survival. Cancer Res (2005) 2.63
Interaction of YY1 with E2Fs, mediated by RYBP, provides a mechanism for specificity of E2F function. EMBO J (2002) 2.49
Gene expression signatures that predict radiation exposure in mice and humans. PLoS Med (2007) 2.38
Patterns of gene expression that characterize long-term survival in advanced stage serous ovarian cancers. Clin Cancer Res (2005) 2.37
Venous thromboembolism: a public health concern. Am J Prev Med (2010) 2.37
Linking oncogenic pathways with therapeutic opportunities. Nat Rev Cancer (2006) 2.32
Comparison of characteristics from White- and Black-Americans with venous thromboembolism: a cross-sectional study. Am J Hematol (2010) 2.26
Gene expression phenotypes of atherosclerosis. Arterioscler Thromb Vasc Biol (2004) 2.23
A genomic strategy to elucidate modules of oncogenic pathway signaling networks. Mol Cell (2009) 2.22
Comparative effectiveness of new oral anticoagulants and standard thromboprophylaxis in patients having total hip or knee replacement: a systematic review. Ann Intern Med (2013) 2.15
Signaling networks that link cell proliferation and cell fate. J Biol Chem (2002) 1.91
Specificity in the activation and control of transcription factor E2F-dependent apoptosis. Proc Natl Acad Sci U S A (2003) 1.89
Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. Am J Hematol (2012) 1.85
Identification of E-box factor TFE3 as a functional partner for the E2F3 transcription factor. Mol Cell Biol (2003) 1.76
Embracing the complexity of genomic data for personalized medicine. Genome Res (2006) 1.75
Prognostic and predictive biomarkers in resected colon cancer: current status and future perspectives for integrating genomics into biomarker discovery. Oncologist (2010) 1.72
Gene expression profiles of multiple breast cancer phenotypes and response to neoadjuvant chemotherapy. Clin Cancer Res (2006) 1.72
Huntingtin is present in the nucleus, interacts with the transcriptional corepressor C-terminal binding protein, and represses transcription. J Biol Chem (2001) 1.70
The PrfA virulence regulon. Microbes Infect (2007) 1.69
Retracted A genomic approach to colon cancer risk stratification yields biologic insights into therapeutic opportunities. Proc Natl Acad Sci U S A (2008) 1.69
Gene expression patterns that characterize advanced stage serous ovarian cancers. J Soc Gynecol Investig (2004) 1.68
Anti-heparin/platelet factor 4 antibody optical density values and the confirmatory procedure in the diagnosis of heparin-induced thrombocytopenia. Thromb Haemost (2008) 1.61
Aspirin exposure reveals novel genes associated with platelet function and cardiovascular events. J Am Coll Cardiol (2013) 1.61
Unfolded protein response genes regulated by CED-1 are required for Caenorhabditis elegans innate immunity. Dev Cell (2008) 1.59
Genomic prediction of locoregional recurrence after mastectomy in breast cancer. J Clin Oncol (2006) 1.57
Validation of the high-dose heparin confirmatory step for the diagnosis of heparin-induced thrombocytopenia. Blood (2010) 1.55
Analysis of Cdc6 function in the assembly of mammalian prereplication complexes. Proc Natl Acad Sci U S A (2002) 1.51
Analysis of sample set enrichment scores: assaying the enrichment of sets of genes for individual samples in genome-wide expression profiles. Bioinformatics (2006) 1.49
Plasmapheresis and heparin reexposure as a management strategy for cardiac surgical patients with heparin-induced thrombocytopenia. Anesth Analg (2009) 1.49
The regulated association of Cdt1 with minichromosome maintenance proteins and Cdc6 in mammalian cells. J Biol Chem (2003) 1.46
Novel tumor sampling strategies to enable microarray gene expression signatures in breast cancer: a study to determine feasibility and reproducibility in the context of clinical care. Breast Cancer Res Treat (2009) 1.46
Retracted An integrated approach to the prediction of chemotherapeutic response in patients with breast cancer. PLoS One (2008) 1.45
Impact of venous thromboembolism and anticoagulation on cancer and cancer survival. J Clin Oncol (2009) 1.45
Gene expression signatures of radiation response are specific, durable and accurate in mice and humans. PLoS One (2008) 1.44
Age-specific differences in oncogenic pathway deregulation seen in human breast tumors. PLoS One (2008) 1.43
A role for E2F6 in distinguishing G1/S- and G2/M-specific transcription. Genes Dev (2004) 1.42
Failure of terminal erythroid differentiation in EKLF-deficient mice is associated with cell cycle perturbation and reduced expression of E2F2. Mol Cell Biol (2008) 1.42
Elevated expression of a subset of interferon inducible genes in primary bone marrow cells expressing p185 Bcr-Abl versus p210 Bcr-Abl by DNA microarray analysis. Leuk Res (2004) 1.41
Randomized trial of physician alerts for thromboprophylaxis after discharge. Am J Med (2013) 1.39
Blockade of tissue factor: treatment for organ injury in established sepsis. Am J Respir Crit Care Med (2003) 1.38
Balancing the decision of cell proliferation and cell fate. Cell Cycle (2009) 1.36
Assays for measuring rivaroxaban: their suitability and limitations. Ther Drug Monit (2010) 1.36
Combinatorial gene control involving E2F and E Box family members. EMBO J (2004) 1.35
Prevalence and clinical characteristics of mental stress-induced myocardial ischemia in patients with coronary heart disease. J Am Coll Cardiol (2013) 1.34
Distinctions in the specificity of E2F function revealed by gene expression signatures. Proc Natl Acad Sci U S A (2005) 1.34
Origin of bistability underlying mammalian cell cycle entry. Mol Syst Biol (2011) 1.32
Blockade of tissue factor-factor X binding attenuates sepsis-induced respiratory and renal failure. Am J Physiol Lung Cell Mol Physiol (2005) 1.31
Prediction of optimal versus suboptimal cytoreduction of advanced-stage serous ovarian cancer with the use of microarrays. Am J Obstet Gynecol (2004) 1.29
Genetic heterogeneity of Myc-induced mammary tumors reflecting diverse phenotypes including metastatic potential. Proc Natl Acad Sci U S A (2009) 1.26